The growing prevalence for performance-enhancing peptides has created a large grey market, offering both novel possibilities and real risks. These unlicensed products, often procured from international laboratories, bypass traditional pharmaceutical routes, allowing access at discounted prices. However, the shortage of quality testing and rigorous